Phase 3 Myeloma Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with multiple myeloma (a type of blood cancer) according to established medical guidelines.
• People whose multiple myeloma is measurable through specific blood, urine, or protein tests meeting set thresholds (confirm with trial site for exact values).
• In Part 1 of the trial: People whose multiple myeloma has come back or stopped responding to treatment, and who have received 1–2 previous rounds of treatment including at least one drug from each of two specific medication classes; OR people newly diagnosed with multiple myeloma who are not suitable candidates for a stem cell transplant, either because they are 65 or older, or because they are younger but have other health conditions that make a transplant unsuitable.
• In Part 2 of the trial: People newly diagnosed with multiple myeloma who are not suitable candidates for high-dose chemotherapy and stem cell transplant, either due to age or due to other significant health conditions that could affect how well they tolerate those treatments.
• People who are reasonably well and able to carry out basic daily activities, as measured by a standard health scoring system (score of 2 or lower on the ECOG scale).
• People who are not pregnant and who are willing to use contraception during the trial.
• For people whose myeloma has returned or stopped responding: People whose side effects from previous treatments have resolved or reduced to a mild level before joining.

Who may not be able to join:

• People who have smouldering multiple myeloma (an early, inactive form of the disease).
• People who have a condition called monoclonal gammopathy of undetermined significance (MGUS), which is a pre-cancer blood condition.
• People who have Waldenström's macroglobulinaemia (a different type of blood cancer).
• People who have plasma cell leukaemia (a rare and aggressive blood cancer).
• People who have an active, uncontrolled infection — including bacterial, fungal, or viral infections such as COVID-19, hepatitis B or C, HIV, or AIDS-related illness.
• People who have had another active cancer within the past 3 years, with exceptions for certain low-risk skin cancers or very early-stage cancers that have been fully treated (confirm with trial site).
• For people whose myeloma has returned or stopped responding: People who have received certain specific targeted treatments (directed at BCMA or CD38) within the 6 months before starting this trial, or who have had a stem cell transplant within the past 3 months, or who are experiencing complications from a previous transplant.
• For people newly diagnosed with multiple myeloma: People who have already received systemic (whole-body) treatment for myeloma, except for a limited short course of a steroid medication; or people who have received above a set cumulative dose of steroid medication during the screening period.
• People who have received a live vaccine (such as some flu or travel vaccines) within 4 weeks before the first dose of the trial treatment.
• People who have taken part in another clinical trial or received an experimental treatment within 30 days before starting this trial (or within a timeframe set by local requirements).

Important: Always verify eligibility with the trial site directly before applying.